Date & Time
May 24, 12:00 PM ET / 9:00 AM PT
Webinar Details provided upon RSVP Approval
About the Event
More than 400,000 new cases of metastatic bone cancer are diagnosed each year in the US, yet there are still over 350,000 deaths from this disease each year. QSAM Biosciences (OTCQB: QSAM) has refined an FDA-approved treatment, creating a heat seeking missile that has the potential to cure metastatic bone cancer.
Join our webinar with QSAM CEO and Director, Douglas Baum to learn about their lead technology, CycloSam®, and its ability to address the $20B bone mets market.